ProShare Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $455K | Sell |
|
|||||
|
2025
Q1 | $406K | Sell |
|
|||||
|
2024
Q4 | $511K | Buy |
|
|||||
|
2024
Q3 | $390K | Buy |
|
|||||
|
2024
Q2 | $236K | Sell |
|
|||||
|
2024
Q1 | $246K | Buy |
|
|||||
|
2023
Q4 | $266K | Buy |
|
|||||
|
2023
Q3 | $262K | Buy |
|
|||||
|
2023
Q2 | $260K | Buy |
|
|||||
|
2023
Q1 | $291K | Sell |
|
|||||
|
2022
Q4 | $451K | Buy |
|
|||||
|
2022
Q3 | $455K | Buy |
|
|||||
|
2022
Q2 | $374K | Sell |
|
|||||
|
2022
Q1 | $860K | Sell |
|
|||||
|
2021
Q4 | $894K | Buy |
|
|||||
|
2021
Q3 | $877K | Sell |
|
|||||
|
2021
Q2 | $1.23M | Buy |
|
|||||
|
2021
Q1 | $729K | Buy |
|
|||||
|
2020
Q4 | $495K | Buy |
|
|||||
|
2020
Q3 | $172K | Buy |
|
|||||
|
2020
Q2 | $232K | Buy |
|
|||||
|
2020
Q1 | $60K | Sell |
|
|||||
|
2019
Q4 | $184K | Buy |
|
|||||
|
2019
Q3 | $122K | Sell |
|
|||||
|
2019
Q2 | $166K | Sell |
|
|||||
|
2019
Q1 | $400K | Buy |
|
|||||
|
2018
Q4 | $393K | Sell |
|
|||||
|
2018
Q3 | $442K | Buy |
|
|||||
|
2018
Q2 | $312K | Sell |
|
|||||
|
2018
Q1 | $277K | Sell |
|
|||||
|
2017
Q4 | $332K | Buy |
|
|||||
|
2017
Q3 | $266K | Buy |
|
|||||
|
2017
Q2 | $269K | Buy |
|
|||||
|
2017
Q1 | $403K | Sell |
|
|||||
|
2016
Q4 | $383K | Buy |
|
|||||
|
2016
Q3 | $237K | Sell |
|
|||||
|
2016
Q2 | $181K | Buy |
|
|||||
|
2016
Q1 | $178K | Sell |
|
|||||
|
2015
Q4 | $718K | Buy |
|
|||||
|
2015
Q3 | $716K | Sell |
|
|||||
|
2015
Q2 | $1M | Sell |
|
|||||
|
2015
Q1 | $645K | Buy |
|
|||||
|
2014
Q4 | $761K | Sell |
|
|||||
|
2014
Q3 | $633K | Sell |
|
|||||
|
2014
Q2 | $977K | Buy |
|
|||||
|
2014
Q1 | $479K | Buy |
|
|||||
|
2013
Q4 | $197K | Buy |
|
|||||
|
2013
Q3 | – | Sell |
|
|||||
|
2013
Q2 | $54K | Buy |
|